Australia markets close in 4 hours 56 minutes
  • ALL ORDS

    7,751.60
    +5.70 (+0.07%)
     
  • ASX 200

    7,545.20
    +6.20 (+0.08%)
     
  • AUD/USD

    0.6894
    +0.0004 (+0.06%)
     
  • OIL

    74.49
    +0.38 (+0.51%)
     
  • GOLD

    1,881.90
    +2.40 (+0.13%)
     
  • BTC-AUD

    33,081.65
    -467.89 (-1.39%)
     
  • CMC Crypto 200

    527.84
    +2.70 (+0.51%)
     
  • AUD/EUR

    0.6421
    +0.0008 (+0.13%)
     
  • AUD/NZD

    1.0920
    +0.0002 (+0.02%)
     
  • NZX 50

    12,119.19
    -77.96 (-0.64%)
     
  • NASDAQ

    12,464.51
    -108.85 (-0.87%)
     
  • FTSE

    7,836.71
    -65.09 (-0.82%)
     
  • Dow Jones

    33,891.02
    -34.99 (-0.10%)
     
  • DAX

    15,345.91
    -130.52 (-0.84%)
     
  • Hang Seng

    21,222.16
    -438.31 (-2.02%)
     
  • NIKKEI 225

    27,693.65
    0.00 (0.00%)
     

Is AbbVie Stock a Buy Now?

Is AbbVie Stock a Buy Now?

Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. Although the way AbbVie is going, an earnings slump is likely to be short-lived. Humira was seen as a blockbuster from the beginning; the rheumatoid arthritis medication brought in $800 million in its first full year of sales in 2003, back when AbbVie was still part of Abbott Laboratories.